Maynard Um
-
-
-
-
-
-
-
LifeSci Capital Downgrades Verve Therapeutics (VERV) to Market Perform
-
-
-
-
-
-
-
Verve Therapeutics (VERV) PT Raised to $24 at Guggenheim
-
-
-
-
-
-
-
Verve Therapeutics (VERV) Announces Positive Initial Data from the Heart-2 Phase 1b Trial of VERVE-102
-
-
-
-
-
-
-
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
-
-
-
-
-
396,364 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

